Nonsentinel lymph nodes key factor in melanoma prognosis

August 2, 2013
Nonsentinel lymph nodes key factor in melanoma prognosis
Nonsentinel lymph node positivity is a significant prognostic factor in patients with stage III melanoma, associated with shorter overall and disease-specific survival, according to research published online July 31 in JAMA Surgery.

(HealthDay)—Nonsentinel lymph node (NSLN) positivity is a significant prognostic factor in patients with stage III melanoma, associated with shorter overall and disease-specific survival, according to research published online July 31 in JAMA Surgery.

Anna M. Leung, M.D., of St. John's Health Center in Santa Monica, Calif., and colleagues searched the database at the John Wayne Cancer Institute and identified patients with (SLNs) positive for cutaneous melanoma who subsequently underwent completion . The survival associated with disease limited to SLNs and disease spread into NSLNs was examined.

The researchers found that 329 of 4,223 patients who underwent SLN biopsy from 1986 to 2012 had a tumor-positive SLN. Of these, 250 patients (76.0 percent) had no additional positive nodes and 79 patients (24.0 percent) had a tumor-positive NSLN. The NSLN-positive group had shorter overall median survival (42.2 versus 178 months), lower rate of five-year overall survival (46.4 versus 72.3 percent), shorter median melanoma-specific survival (60 months versus not yet reached), and lower rate of five-year melanoma-specific survival (49.5 versus 77.8 percent) than the SLN-only positive group.

"We propose that, for the next iteration of the , the committee performs an analysis of the independent prognostic impact of NSLN status," the authors write.

More information: Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Related Stories

Tumor-Infiltrating lymphocyte grade IDs melanoma survival

June 20, 2012

(HealthDay) -- Tumor-infiltrating lymphocyte (TIL) grade is an independent predictor of melanoma-specific survival and sentinel lymph node (SLN) status in patients with localized primary cutaneous melanoma, according to a ...

Sentinel node biopsy safe for vulvar squamous cell cancer

July 8, 2012

(HealthDay) -- For women with squamous cell carcinoma (SCC) of the vulva, sentinel lymph node (SLN) biopsy may be safely used in place of inguinal femoral lymphadenectomy, according to research published online July 2 in ...

Researchers study childhood melanoma characteristics

September 7, 2012

Melanoma, newly diagnosed in more than 76,000 Americans in 2011, is the most common and dangerous form of skin cancer. Melanoma is rare in children, accounting for 1 to 4 percent of all melanoma cases and just 3 percent of ...

Recommended for you

A recipe for long-lasting livers

April 22, 2015

People waiting for organ transplants may soon have higher hopes of getting the help that they need in time. Researchers at the RIKEN Center for Developmental Biology have developed a new technique that extends the time that ...

Surgeon to offer ideas on a way to do human head transplants

February 26, 2015

Sergio Canavero of the Turin Advanced Neuromodulation Group has made it known that he intends to announce at this summer's American Academy of Neurological and Orthopedic Surgeons meeting, that he believes he has put together ...

New tool helps guide brain cancer surgery

July 3, 2014

A tool to help brain surgeons test and more precisely remove cancerous tissue was successfully used during surgery, according to a Purdue University and Brigham and Women's Hospital study.

New imaging technique sharpens surgeons' vision

February 11, 2014

Which superhuman power would you choose for help on the job? For Dr. Julie Margenthaler, it's a technology that brings to mind X-ray vision, used for the first time Monday during an operation to remove a patient's lymph node.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.